Uncategorized

Compass’ psilocybin depression drug works for the long haul

Published

on

New data from a Phase 3 trial will further support a rolling submission for Compass Pathways’ psilocybin treatment COMP360. Patients who saw a clinically meaningful benefit on depression severity maintained response through week 26.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version